From cost-buster blockbusters to epic genetics
This article was originally published in Scrip
Executive Summary
We are all used to reading prognostications about the state of the pharmaceutical industry, be they from industry insiders or from consultancy or financial firms that focus on this particular area. However, analyses from outside the industry and the broader pharmaceutical community are few and far between, which makes a report just published by Chatham House particularly interesting reading.